Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 29;6(8):e764. doi: 10.1097/HS9.0000000000000764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 2. — Inhibition (%) of SARS-CoV-2 binding after vaccination with the BNT162b2 mRNA vaccine in patients with MM, before and 1 month after the fourth dose. Patients were classified into 3 categories based on their treatment: (A) those anti-CD38 based treatment (N = 43), (B) those receiving anti-BCMA-based treatment (N = 21), and (C) those receiving any other treatment (N = 137). The single asterisk (*) indicates statistically significant differences (P < 0.05) between the compared groups. The double asterisk (**) indicates a significant difference for the same group between the 2 occasions (before and after the fourth vaccination). The boundaries of the box plot refer to the quartiles of the distribution, while the dashed lines of the graph indicate the limits of inhibition, that is, 30%, 50%, and 75%.